MAVEN BIO99 2 PhD’s hits 2 GRAND SLAMS setting up for APPROVALS courtesy Of UNSTOPPABLE CEO Linda Powers with clandestine BACKSTOPS beyond the LEGAL!(uncovered by DStock!)
Bio99 (@BIO99_BIO99) tweeted at 1:48 AM on Sat, Jul 22, 2023: $NWBO 27 modules ready to go and being checked for consistency, said Les Goldman on the Big Biz show. Considering the FDA application needs 5-9 depending on the source, 27 is enough for 4-6 regulators… fireworks coming… (https://twitter.com/BIO99_BIO99/status/1682628789296324608?t=L1f57Xl3D6S7D3t8uT_CDA&s=03)
Bio99 (@BIO99_BIO99) tweeted at 9:50 AM on Sun, Jul 23, 2023: $NWBO ASCO2022 slide from Shashi Murthy showing just how automated DCVax is set up to be… any surprise that regulators like MHRA are rush preparing for approving POC manufacturing? Every hospital on Earth will have at least one of these soon… that’s called real scaling… (https://twitter.com/BIO99_BIO99/status/1683112367826284545?t=x17V4kgWXRdW5FUddKkdQA&s=03)
CLANDESTINE BACKSTOP US GOVT BACKED $200 MLN STARTUP backed by dedicated & FOCUSED Venture Capitalists!
Battelle, Partners to Form New Company: AmplifyBio $200 million start-up will focus on development of next generation therapies
May 03, 2021 11:00 AM Eastern Daylight Time
COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle announced today that it is launching a new company that will focus on the research and development of next generation therapies such as cell and gene therapies (CGT). AmplifyBio will operate on its own 30-acre dedicated footprint within Battelle’s West Jefferson, Ohio campus. The new company has the backing of Battelle and several outside investors with extensive experience in the life sciences and pharmaceutical markets.
“Combining the strength of Battelle with our investors will uniquely position us for rapid growth and the potential to help millions of people around the world.” Tweet this AmplifyBio will work to accelerate the development of next generation therapies by creating and optimizing new platforms and technologies and working to solve the challenges of scaling complex therapies to help as many people as possible. Battelle’s core life sciences research business is the starting point for this standalone, for-profit company. CGT has the potential to deliver cures and life changing treatments for dozens of diseases that today have no effective options.
In addition to Battelle, investors in the new company include Viking Capital Investments, Casdin Capital and Narya Capital Fund. Battelle will have two seats on AmplifyBio’s five-person board of directors.
“For decades, Battelle has found new ways to innovate,” said Lou Von Thaer, President and CEO of Battelle. “AmplifyBio is a $200 million start-up with the backing of respected investors who will help us to move quickly and intelligently in this rapidly developing field of research.”
AmplifyBio will purchase an existing building and surrounding land on the Battelle campus. The 210,000-square-foot facility has state-of-the-art laboratory space and equipment that will help the new company accelerate research into novel cell and gene therapies, while also maintaining a steady stream of current contract research work for commercial customers.
J. Kelly Ganjei has been appointed President and CEO of the new company, and he has begun the process of finalizing his leadership team. Until recently, Ganjei was the CEO of Cognate BioServices, Inc.He is a respected leader with more than 26 years of experience in the life science, venture capital and IT sectors. Ganjei has been instrumental in working with several regenerative medicine and cell therapy companies, achieving significant clinical and business milestones. Under his leadership, Cognate grew from relative obscurity to the leading international CDMO for cell and gene therapy with revenue in excess of $120 million, and manufacturing facilities in the US, the UK and Sweden.
“There is great potential for advanced medicines to help so many patients across a diverse set of conditions, but there is no shortage of technical problems to solve across this sector. The earlier in their development lifecycle we can help these products the better the outcome for everyone,” Ganjei said. “Combining the strength of Battelle with our investors will uniquely position us for rapid growth and the potential to help millions of people around the world.”
“This is why Battelle exists—to happen to the world,” Von Thaer said. “We see a need, we see opportunities, we search for partnerships, and we keep Battelle at the leading edge of discovery for the benefit of humanity. I’m excited to see where the team takes AmplifyBio and proud to support its growth through our continued involvement.”
About Battelle
Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org.
Contacts Katy Delaney at (614) 424-7208 or delaneyk@battelle.org T.R. Massey at (614) 424-5544 or masseytr@battelle.org
https://www.businesswire.com/news/home/20210503005527/en/Battelle-Partners-to-Form-New-Company-AmplifyBio As an expert contract research organization (CRO), AmplifyBio leverages decades of experience to create modern commercial drug development solutions. From CRO and preclinical CRO needs to cell and gene therapy and advanced therapy testing, our accredited team designs innovative paths to produce globally recognized studies, services, and more.
AmplifyBio’s success over the past two yearshas been fueled by its talented and dedicated team, which has grown from 125 at launch to over 300 employees today. The company’s leadership team brings a wealth of experience in biopharmaceuticals, manufacturing, and technology development and is committed to driving innovation in the industry.
In addition to expanding its team, AmplifyBio has increased preclinical CRO study capacity and invested in technologies in analytics, pathology, and data handling that ensure AmplifyBio is on the cutting edge of technologies that advance preclinical research expeditiously. The result of that work is that AmplifyBio has added 35 new customers and reported 15 consecutive months of 99% on-time reporting rate on commercial preclinical studies. https://www.amplify-bio.com/amplifybio-celebrates-2-years-of-innovative-solutions-in-preclinical-drug-development-and-safety/
maverick_1 (@maveric92283613) tweeted at 9:47 AM on Mon, Jul 17, 2023: I was blown away when I came across this courtesy of a DEEP digger & you will be as well: Impressive dedicated Venture Capital backers aligned w/a GIANT Developmental Orgnztn where many new technologies BLOSSOM
I am so far behind in my personal priorities: gave it to a lawyer. (
I was blown away when I came across this courtesy of a DEEP digger & you will be as well: Impressive dedicated Venture Capital backers aligned w/a GIANT Developmental Orgnztn where many new technologies BLOSOM
I am so far behind in my personal priorities: gave it to a lawyer.
Building TSUNAMI for DARK Forces: Market is RIGGED (Severe Limits of Capitalism via exploiting loopholes w/ IT in modern day version of “WILD WEST” of emptying out pockets!)
In life: Do it right on the the FIRST TRY: Few second chances.
GENERATIONAL RETURNS!
Since 2020, allowed ONE post daily for INFINITY: Arbitrary….. FACTS versus attack!
AI
